Update on disease-modifying therapies for multiple sclerosis

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Investigative Medicine

• Publication date

  2017-01-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/jim-2016-000339PMID 28130412
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mechanism of Action

  2020cited by this paper
• Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets

  2019cited by this paper
• Efficacy and Safety of Ocrelizumab in Primary Progressive Multiple Sclerosis: Results of the Phase III Double-Blind, Placebo-Controlled ORATORIO Study (S49.001)

  2016cited by this paper
• Cutaneous adverse events in multiple sclerosis patients treated with daclizumab

  2016cited by this paper
• The use of immune modulating drugs for the treatment of multiple sclerosis

  2016cited by this paper
• Fingolimod-associated PML in a patient with prior immunosuppression

  2016cited by this paper
• Immunological treatment of multiple sclerosis.

  2016cited by this paper
• Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets

  2016cited by this paper
• The role of global and regional gray matter volume decrease in multiple sclerosis

  2016cited by this paper
• Fingolimod in the treatment of relapsing–remitting multiple sclerosis: long-term experience and an update on the clinical evidence

  2016cited by this paper
• Secondary Progressive Multiple Sclerosis: Definition and Measurement

  2016cited by this paper
• Defining secondary progressive multiple sclerosis.

  2016cited by this paper
• PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter?

  2016cited by this paper
• Current multiple sclerosis treatments have improved our understanding of MS autoimmune pathogenesis

  2016cited by this paper
• Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study

  2016cited by this paper
• [Pegylated interferon beta-1a on the Italian market]

  2016cited by this paper
• An update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerations

  2015cited by this paper
• Glatiramer Acetate 40 Mg/Ml Three Times A Week for The Treatment of Relapsing Forms of Multiple Sclerosis: Potential Cost Benefits of A Regimen With Infrequent Injections Which May Minimise Switching to The Newly-Introduced First-Line and Second-Line Disease Modifying Therapies.

  2015cited by this paper
• Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group

  2015cited by this paper
• Fingolimod treatment promotes regulatory phenotype and function of B cells

  2015cited by this paper
• Monoclonal Antibodies for Multiple Sclerosis Treatment.

  2015cited by this paper
• The neuronal component of gray matter damage in multiple sclerosis: A [11C]flumazenil positron emission tomography study

  2015cited by this paper
• Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

  2015cited by this paper
• PML in a patient with lymphocytopenia treated with dimethyl fumarate.

  2015cited by this paper
• PML in a patient without severe lymphocytopenia receiving dimethyl fumarate.

  2015cited by this paper
• PML in Patients Treated with Dimethyl Fumarate.

  2015cited by this paper
• Gray matter damage in multiple sclerosis: Impact on clinical symptoms.

  2015cited by this paper
• PML in Patients Treated with Dimethyl Fumarate.

  2015cited by this paper
• PML in Patients Treated with Dimethyl Fumarate.

  2015cited by this paper
• Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing–remitting multiple sclerosis (RRMS)

  2015cited by this paper
• B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic Interventions

  2015cited by this paper
• Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes

  2015cited by this paper
• The autoimmune pathogenesis of multiple sclerosis.

  2015cited by this paper
• Dimethyl fumarate in the treatment of relapsing–remitting multiple sclerosis: an overview

  2015cited by this paper
• Teriflunomide: a once-daily oral medication for the treatment of relapsing forms of multiple sclerosis.

  2015cited by this paper
• Natalizumab to fingolimod washout in patients at risk of PML

  2014cited by this paper
• Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials

  2014cited by this paper
• Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial

  2014cited by this paper
• Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy

  2014cited by this paper
• Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects

  2014cited by this paper
• Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (III).

  2014cited by this paper
• PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation

  2014cited by this paper
• Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.

  2014cited by this paper
• Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis

  2014cited by this paper
• Natalizumab treatment for multiple sclerosis.

  2014cited by this paper
• The Effectiveness of Dimethyl Fumarate Monotherapy in the Treatment of Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis

  2014cited by this paper
• Gender and autoimmune comorbidity in multiple sclerosis

  2014cited by this paper
• Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.

  2014cited by this paper
• Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.

  2014cited by this paper
• Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safety

  2014cited by this paper
• Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial.

  2014cited by this paper
• Teriflunomide (Aubagio®) for the treatment of multiple sclerosis.

  2014cited by this paper
• Randomized study combining interferon and glatiramer acetate in multiple sclerosis

  2013cited by this paper
• The pharmacokinetics of glatiramer acetate for multiple sclerosis treatment

  2013cited by this paper
• Review of daclizumab and its therapeutic potential in the treatment of relapsing–remitting multiple sclerosis

  2013cited by this paper
• Teriflunomide for the Treatment of Relapsing Multiple Sclerosis

  2013cited by this paper
• The Immune Pathogenesis of Multiple Sclerosis

  2013cited by this paper
• Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis

  2013cited by this paper
• Dimethyl Fumarate for Treatment of Multiple Sclerosis: Mechanism of Action, Effectiveness, and Side Effects

  2013cited by this paper
• Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.

  2013cited by this paper
• Dimethyl fumarate (BG-12) for the treatment of multiple sclerosis

  2013cited by this paper
• The cost burden of multiple sclerosis in the United States: a systematic review of the literature

  2013cited by this paper
• Teriflunomide - a new oral agent for multiple sclerosis treatment.

  2013cited by this paper
• PML in a patient treated with dimethyl fumarate from a compounding pharmacy.

  2013cited by this paper
• Signals of progressive multifocal leukoencephalopathy for immunosuppressants: a disproportionality analysis of spontaneous reports within the US Adverse Event Reporting System (AERS)

  2012cited by this paper
• Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.

  2012cited by this paper
• Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

  2012cited by this paper
• Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.

  2012cited by this paper
• Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.

  2012cited by this paper
• Progressive multiple sclerosis: pathology and pathogenesis

  2012cited by this paper
• Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II).

  2012cited by this paper
• The interferon beta therapies for treatment of relapsing–remitting multiple sclerosis: are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alone or in combination

  2011cited by this paper
• Fingolimod for the treatment of relapsing multiple sclerosis

  2011cited by this paper
• Multiple sclerosis: Teriflunomide shows promise for MS treatment in phase III trial

  2011cited by this paper
• Multiple sclerosis: advances in understanding pathogenesis and emergence of oral treatment options

  2011cited by this paper
• Fingolimod: The first oral drug approved by food and drug administration; A breakthrough in treatment of multiple sclerosis

  2011cited by this paper
• Multiple Sclerosis: Pathogenesis and Treatment

  2011cited by this paper
• Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

  2011cited by this paper
• Alzheimer Disease: Amyloid-targeting antibody performs well in phase II trial

  2011cited by this paper
• Oral fingolimod for the treatment of relapsing-remitting multiple sclerosis.

  2010cited by this paper
• Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis

  2010cited by this paper
• Glatiramer acetate: successful desensitization for treatment of multiple sclerosis.

  2010cited by this paper
• Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.

  2010cited by this paper
• The mechanism of action of glatiramer acetate treatment in multiple sclerosis

  2010cited by this paper
• Improvement of health-related quality of life in relapsing remitting multiple sclerosis patients after 2 years of treatment with intramuscular interferon-beta-1a

  2010cited by this paper
• Environmental factors and their timing in adult-onset multiple sclerosis

  2010cited by this paper
• Oral fingolimod for relapsing-remitting multiple sclerosis

  2010cited by this paper
• PEGylated Interferon Beta-1a: Meeting an Unmet Medical Need in the Treatment of Relapsing Multiple Sclerosis

  2010cited by this paper
• Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

  2010cited by this paper
• New drugs may improve, complicate treatment for multiple sclerosis

  2010cited by this paper
• Good results for early treatment of clinically isolated syndrome prior to multiple sclerosis with interferon beta-1b and glatiramer group

  2010cited by this paper
• Long-term treatment of multiple sclerosis with glatiramer acetate: natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy.

  2010cited by this paper
• Specific immune intervention with monoclonal antibodies for the treatment of multiple sclerosis.

  2010cited by this paper
• A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

  2010cited by this paper
• Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

  2010cited by this paper
• Effects of immunomodulatory treatment with subcutaneous interferon beta-1a oncognitive decline in mildly disabled patients with relapsing—remitting multiple sclerosis

  2010cited by this paper
• The role of natalizumab in the treatment of multiple sclerosis.

  2010cited by this paper
• Alemtuzumab in the treatment of relapsing–remitting multiple sclerosis

  2010cited by this paper
• 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.

  2009cited by this paper
• Review of teriflunomide and its potential in the treatment of multiple sclerosis

  2009cited by this paper

• Empowering yet challenging: managing multiple sclerosis in the workplace—an interview study

  2026cites this paper
• Treatment of The Relapsing Remitting Form of Multiple Sclerosis with Benztropine: A Case Report

  2025cites this paper
• The use of implementation strategies to promote the uptake of psychological therapies among people with multiple sclerosis: A scoping review protocol

  2025cites this paper
• Kynurenine Pathway Modulation by Exercise in Multiple Sclerosis: Implications for Neuroprotection and Inflammation

  2025cites this paper
• Harnessing Artificial Intelligence for the Diagnosis, Treatment and Research of Multiple Sclerosis

  2025cites this paper
• Edaravone Inhibits Inflammation in Toll-Like Receptor 4-Stimulated PBMNCs from Multiple Sclerosis Patients

  2025cites this paper
• Effects of Lycium barbarum polysaccharide on the activation of pathogenic CD4+ T cells in a mouse model of multiple sclerosis.

  2025cites this paper
• Betaine alleviates deficits in motor behavior, neurotoxic effects, and neuroinflammatory responses in a rat model of demyelination

  2025cites this paper
• Biodegradable Electrospun PLGA Nanofibers-Encapsulated Trichinella Spiralis Antigens Protect from Relapsing Experimental Autoimmune Encephalomyelitis and Related Gut Microbiota Dysbiosis

  2025cites this paper
• Maintaining Mobility and Balance in Multiple Sclerosis: A Systematic Review Examining Potential Impact of Symptomatic Pharmacotherapy

  2025cites this paper
• Review of multiple sclerosis: Epidemiology, etiology, pathophysiology, and treatment

  2024cites this paper
• Family planning and contraception in people with multiple sclerosis: perspectives for obstetricians, gynaecologists, and other health care professionals involved in reproductive planning

  2024cites this paper
• Elevated frequencies of activated memory B cells in multiple sclerosis are reset to healthy control levels after B cell depletion with Ocrelizumab.

  2024cites this paper
• Safety and efficacy of extended versus standard interval dosing of natalizumab in multiple sclerosis patients: a systematic review and meta-analysis

  2024cites this paper
• Recent trends in disease-modifying therapy use and associated sickness absence and disability pension among people with multiple sclerosis in Sweden

  2024cites this paper
• Longitudinal assessment of neurocognitive function in people with relapsing multiple sclerosis initiating alemtuzumab in routine clinical practice: LEM-COG study results.

  2023cites this paper
• The Development of the Combination Drug Leukovir® Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review.

  2023cites this paper
• The disease-modifying therapy utilisation and cost trend for multiple sclerosis in Australia between 2013 and 2022

  2023cites this paper
• CERVICAL DYSPLASIA RISK IN MULTIPLE SCLEROSIS PATIENTS

  2023cites this paper
• Dyadic coping strategies and quality of care experience: An original study of patients living with multiple sclerosis and their caregivers.

  2023cites this paper
• Predictors of therapeutic failure in multiple sclerosis: a Brazilian center’s experience.

  2023influential citation
• Clinical features of MOGAD with brainstem involvement in the initial attack versus NMOSD and MS.

  2023cites this paper
• Intravesical injections of botulinum neurotoxin A to treat overactive bladder and/or detrusor overactivity related to multiple sclerosis: 5-Year continuation rate and specific risk factors for discontinuation—A study from the neuro-urology committee of the French Association of Urology

  2023cites this paper
• Iranian specialists’ approach to treatment escalation in multiple sclerosis patients with cognitive impairment

  2023cites this paper
• A Dual Therapy of Nanostructured Lipid Carrier Loaded with Teriflunomide—A Dihydro-Orotate Dehydrogenase Inhibitor and an miR-155-Antagomir in Cuprizone-Induced C57BL/6J Mouse

  2023cites this paper
• Vascular disease risk factors in multiple sclerosis: Effect on metabolism and brain volumes.

  2023cites this paper
• Factors associated with the misdiagnosis of neuromyelitis optica spectrum disorder.

  2023cites this paper
• Increased Remyelination and Proregenerative Microglia Under Siponimod Therapy in Mechanistic Models

  2022cites this paper
• Drug repurposing of ilepcimide that ameliorates experimental autoimmune encephalomyelitis via restricting inflammatory response and oxidative stress.

  2022cites this paper
• [Experience of remote rehabilitation for patients with multiple sclerosis].

  2022cites this paper
• Cell‐based experimental strategies for myelin repair in multiple sclerosis

  2022cites this paper
• Trends and Perspectives of Biological Drug Approvals by the FDA: A Review from 2015 to 2021

  2022cites this paper
• Interferon-β Decreases the Hypermetabolic State of Red Blood Cells from Patients with Multiple Sclerosis.

  2022cites this paper
• Health-related quality of life of patients with multiple sclerosis: Analysis of ten years of national data.

  2022cites this paper
• The incidence and prevalence, diagnosis, and treatment of multiple sclerosis in China: a narrative review

  2022cites this paper
• An Accurate Multiple Sclerosis Detection Model Based on Exemplar Multiple Parameters Local Phase Quantization: ExMPLPQ

  2022cites this paper
• Clinical Characteristics and Outcomes of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder With Brainstem Lesions as Heralding Prodrome

  2022cites this paper
• Deformation-based morphometry identifies deep brain structures protected by ocrelizumab

  2022cites this paper
• Neurologic Diseases

  2021cites this paper
• Neuroprotective Properties of Dimethyl Fumarate Measured by Optical Coherence Tomography in Non-inflammatory Animal Models

  2021cites this paper
• When tumefactive demyelination is truly a tumor: case report of a radiographic misdiagnosis

  2021cites this paper
• OIP5-AS1 facilitates Th17 differentiation and EAE severity by targeting miR-140-5p to regulate RhoA/ROCK2 signaling pathway.

  2021cites this paper
• Comparison of the Efficacy and Safety of Anti-CD20 B Cells Depleting Drugs in Multiple Sclerosis.

  2021cites this paper
• Preclinical Therapy with Vitamin D3 in Experimental Encephalomyelitis: Efficacy and Comparison with Paricalcitol

  2021cites this paper
• Brain connectivity and motor improvements after ballet intervention in multiple sclerosis: pilot

  2021cites this paper
• Disease modifying therapies in relapsing-remitting multiple sclerosis: A systematic review and network meta-analysis.

  2021cites this paper
• Detection of Dysbiosis and Increased Intestinal Permeability in Brazilian Patients with Relapsing–Remitting Multiple Sclerosis

  2021cites this paper
• Cutaneous Side Effects of First/Second Line Oral Disease-Modifying Treatments in Patients with Multiple Sclerosis

  2021cites this paper
• N-acetylcysteine protects against cuprizone-induced demyelination: histological and immunohistochemical study.

  2021cites this paper
• Place de l’ocrelizumab dans la prise en charge de la sclérose en plaque : enjeux pour le pharmacien hospitalier

  2021cites this paper
• The Synergistic Anti-Apoptosis Effects of Amniotic Epithelial Stem Cell Conditioned Medium and Ponesimod on the Oligodendrocyte Cells

  2021cites this paper
• Disease-modifying therapy usage in patients with multiple sclerosis in France: A 6-year population-based study.

  2021cites this paper
• Data Visualization for Interdisciplinary Medical Research (Pilot Study)

  2021cites this paper
• Electronic pill bottles to monitor and promote medication adherence for people with multiple sclerosis: A randomized, virtual clinical trial.

  2021cites this paper
• Latent tuberculosis infection reactivation in patients with multiple sclerosis in use of disease-modifying therapies: A systematic review.

  2021cites this paper
• Indirect comparisons of siponimod with fingolimod and ofatumumab in multiple sclerosis: assessing the feasibility of propensity score matching analyses

  2021cites this paper
• Multiple Sclerosis and the Endogenous Opioid System

  2021cites this paper
• Shared decision making and disease modifying therapy in families of children and adolescents with pediatric onset multiple sclerosis.

  2021cites this paper
• Teriflunomide levels in women whose male sexual partner is on teriflunomide for relapsing multiple sclerosis.

  2021cites this paper
• Autologous Hematopoietic Cell Transplant for Patients With Multiple Sclerosis

  2021cites this paper
• Outcome of COVID-19 infection in multiple sclerosis patients receiving disease-modifying therapies

  2021cites this paper
• Tumor Necrosis Factor Alpha Blockade and Multiple Sclerosis: Exploring New Avenues

  2021influential citation
• Demonstration of Equivalence of Generic Glatiramer Acetate and Copaxone®

  2021cites this paper
• Endogenous T Cell Receptor Rearrangement Represses Aggressive Central Nervous System Autoimmunity in a TcR-Transgenic Model on the Non-Obese Diabetic Background

  2020cites this paper
• Inflammatory Role of TLR-MyD88 Signaling in Multiple Sclerosis

  2020cites this paper
• Revisiting the Pathoetiology of Multiple Sclerosis: Has the Tail Been Wagging the Mouse?

  2020cites this paper
• The Effect of Broad-Spectrum Dietary Supplementation on Quality of Life, Symptom Severity, and Functioning in Multiple Sclerosis

  2020cites this paper
• Recent Advances in Nanomedicines for Multiple Sclerosis Therapy.

  2020cites this paper
• Development of a CD19 PET tracer for detecting B cells in a mouse model of multiple sclerosis

  2020cites this paper
• Saliva immunoglobulin free light chain analysis for monitoring disease activity and response to treatment in multiple sclerosis.

  2020cites this paper
• Ab locks for improving the selectivity and safety of antibody drugs

  2020cites this paper
• Comprehensive Analysis of the Immune and Stromal Compartments of the CNS in EAE Mice Reveal Pathways by Which Chloroquine Suppresses Neuroinflammation

  2020cites this paper
• РАСПРОСТРАНЕННОСТЬ АНТИТЕЛ ПРОТИВ ВИРУСА ДЖОНА КАННИНГЕМА У ПАЦИЕНТОВ С РАССЕЯННЫМ СКЛЕРОЗОМ –КАК СТРАТИФИКАЦИЯ СТЕПЕНИ РИСКА ПРОГРЕССИРУЮЩЕЙ МУЛЬТИФОКАЛЬНОЙ ЛЕЙКОЭНЦЕФАЛОПАТИИПРИ ДАННОМ ЗАБОЛЕВАНИИ

  2020cites this paper
• Marginal Health Care Expenditure Burden Among U.S. Civilian Noninstitutionalized Individuals with Multiple Sclerosis: 2010-2015

  2020cites this paper
• JC Polyomavirus Infection Potentiated by Biologics.

  2020cites this paper
• Feature selection based on differentially correlated gene pairs reveals the mechanism of IFN-β therapy for multiple sclerosis

  2020cites this paper
• Use of disease modifying agents in patients with multiple sclerosis: Analysis of ten years of national data.

  2020cites this paper
• CD8 T-cell Recruitment Into the Central Nervous System of Cuprizone-Fed Mice: Relevance to Modeling the Etiology of Multiple Sclerosis

  2020cites this paper
• Alemtuzumab for relapsing multiple sclerosis in clinical practice: A four-year retrospective one-center study

  2020cites this paper
• A common genetic variant rs2821557 in KCNA3 is linked to the severity of multiple sclerosis

  2020cites this paper
• Immunosuppression in relapsing remitting multiple sclerosis: moving towards personalized treatment.

  2020cites this paper
• Recent advances of long noncoding RNAs involved in the development of multiple sclerosis.

  2020cites this paper
• Labeling of Disease-Modifying Therapies for Neurodegenerative Disorders

  2019cites this paper
• Differential multiple sclerosis treatment allocation between Australia and New Zealand associated with clinical outcomes but not mood or quality of life.

  2019cites this paper
• Assessing the anterior visual pathway in optic neuritis: recent experimental and clinical aspects

  2019cites this paper
• Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Sclerosis.

  2019cites this paper
• Suppression of the Peripheral Immune System Limits the Central Immune Response Following Cuprizone-Feeding: Relevance to Modelling Multiple Sclerosis

  2019cites this paper
• CNS inflammatory demyelinating disorders: MS, NMOSD and MOG antibody associated disease

  2019cites this paper
• NURR1 Impairment in Multiple Sclerosis

  2019cites this paper
• Behavioural phenotypes in the cuprizone model of central nervous system demyelination.

  2019cites this paper
• Flammer syndrome in multiple sclerosis: diagnostics, prediction, and personalization of treatments

  2019cites this paper
• Models and treatments for traumatic optic neuropathy and demyelinating optic neuritis

  2019cites this paper
• The real-world effectiveness of natalizumab and fingolimod in relapsing-remitting multiple sclerosis. An Italian multicentre study.

  2019cites this paper
• Polypharmacy in patients with multiple sclerosis: a gender-specific analysis

  2019cites this paper
• Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing–remitting multiple sclerosis: a systematic review and network meta-analysis

  2019cites this paper
• Repurposing multiple sclerosis drugs: a review of studies in neurological and psychiatric conditions.

  2019cites this paper
• Novel CMKLR1 Inhibitors for Application in Demyelinating Disease

  2019cites this paper
• Fingolimod in multiple sclerosis: profile of use in habitual practice

  2019cites this paper
• Case Report: Fingolimod and Cryptococcosis: Collision of Immunomodulation with Infectious Disease.

  2019cites this paper
• Adverse events and monitoring requirements associated with monoclonal antibody therapy in patients with multiple sclerosis

  2019cites this paper